SG11202111172QA - Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy - Google Patents
Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophyInfo
- Publication number
- SG11202111172QA SG11202111172QA SG11202111172QA SG11202111172QA SG11202111172QA SG 11202111172Q A SG11202111172Q A SG 11202111172QA SG 11202111172Q A SG11202111172Q A SG 11202111172QA SG 11202111172Q A SG11202111172Q A SG 11202111172QA SG 11202111172Q A SG11202111172Q A SG 11202111172QA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- muscular dystrophy
- aav vector
- duchenne muscular
- mediated deletion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962833760P | 2019-04-14 | 2019-04-14 | |
PCT/US2020/028148 WO2020214609A1 (en) | 2019-04-14 | 2020-04-14 | Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111172QA true SG11202111172QA (en) | 2021-11-29 |
Family
ID=72837591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111172QA SG11202111172QA (en) | 2019-04-14 | 2020-04-14 | Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220184229A1 (en) |
EP (1) | EP3931331A4 (en) |
JP (1) | JP2022529631A (en) |
KR (1) | KR20210151916A (en) |
CN (1) | CN113785063A (en) |
AR (1) | AR118670A1 (en) |
AU (1) | AU2020257898A1 (en) |
BR (1) | BR112021020515A2 (en) |
CA (1) | CA3137248A1 (en) |
CL (1) | CL2021002680A1 (en) |
CO (1) | CO2021013692A2 (en) |
EA (1) | EA202192815A1 (en) |
IL (1) | IL287163A (en) |
MX (1) | MX2021012511A (en) |
SG (1) | SG11202111172QA (en) |
TW (1) | TW202104594A (en) |
WO (1) | WO2020214609A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
KR20180038558A (en) | 2015-08-25 | 2018-04-16 | 듀크 유니버시티 | Compositions and methods for improving specificity in genomic manipulation using RNA-guided endonuclease |
US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
WO2022087321A1 (en) * | 2020-10-21 | 2022-04-28 | Duke University | Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy |
AU2022344251A1 (en) * | 2021-09-08 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Serpina-modulating compositions and methods |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014274840B2 (en) * | 2013-06-05 | 2020-03-12 | Duke University | RNA-guided gene editing and gene regulation |
US20180353615A1 (en) * | 2015-11-30 | 2018-12-13 | Charles A. Gersbach | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
WO2017139505A2 (en) * | 2016-02-11 | 2017-08-17 | The Regents Of The University Of California | Methods and compositions for modifying a mutant dystrophin gene in a cell's genome |
WO2019067786A1 (en) * | 2017-09-29 | 2019-04-04 | The Regents Of The University Of California | A multi-armed polyrotaxane platform for protected nucleic acid delivery |
-
2020
- 2020-04-14 US US17/603,330 patent/US20220184229A1/en active Pending
- 2020-04-14 CN CN202080028248.2A patent/CN113785063A/en active Pending
- 2020-04-14 AU AU2020257898A patent/AU2020257898A1/en active Pending
- 2020-04-14 BR BR112021020515A patent/BR112021020515A2/en unknown
- 2020-04-14 JP JP2021560849A patent/JP2022529631A/en active Pending
- 2020-04-14 WO PCT/US2020/028148 patent/WO2020214609A1/en active Application Filing
- 2020-04-14 KR KR1020217036783A patent/KR20210151916A/en unknown
- 2020-04-14 CA CA3137248A patent/CA3137248A1/en active Pending
- 2020-04-14 SG SG11202111172QA patent/SG11202111172QA/en unknown
- 2020-04-14 MX MX2021012511A patent/MX2021012511A/en unknown
- 2020-04-14 EP EP20790851.8A patent/EP3931331A4/en active Pending
- 2020-04-14 TW TW109112555A patent/TW202104594A/en unknown
- 2020-04-14 AR ARP200101048A patent/AR118670A1/en unknown
- 2020-04-14 EA EA202192815A patent/EA202192815A1/en unknown
-
2021
- 2021-10-11 IL IL287163A patent/IL287163A/en unknown
- 2021-10-13 CL CL2021002680A patent/CL2021002680A1/en unknown
- 2021-10-14 CO CONC2021/0013692A patent/CO2021013692A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA202192815A1 (en) | 2022-01-24 |
EP3931331A1 (en) | 2022-01-05 |
AR118670A1 (en) | 2021-10-20 |
CN113785063A (en) | 2021-12-10 |
CA3137248A1 (en) | 2020-10-22 |
JP2022529631A (en) | 2022-06-23 |
WO2020214609A1 (en) | 2020-10-22 |
EP3931331A4 (en) | 2022-11-30 |
AU2020257898A1 (en) | 2021-11-04 |
CL2021002680A1 (en) | 2022-07-15 |
MX2021012511A (en) | 2022-01-06 |
TW202104594A (en) | 2021-02-01 |
KR20210151916A (en) | 2021-12-14 |
US20220184229A1 (en) | 2022-06-16 |
CO2021013692A2 (en) | 2022-01-17 |
BR112021020515A2 (en) | 2022-01-04 |
IL287163A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287163A (en) | Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy | |
IL283123A (en) | Method for treating muscular dystrophy by targeting utrophin gene | |
IL288523A (en) | Compounds for treatment of pd-l1 diseases | |
SG11202006722RA (en) | Gene therapy for limb-girdle muscular dystrophy type 2c | |
EP3917566A4 (en) | Methods for using transcription-dependent directed evolution of aav capsids | |
EP4013770A4 (en) | Aav capsid variants for gene therapy | |
IL275838A (en) | A modified raav capsid protein for gene therapy | |
IL277745A (en) | Use of fubp1 inhibitors for treating hepatitis b virus infection | |
EA201890543A1 (en) | METHODS AND MATERIALS FOR GALGT2 GENE THERAPY | |
IL279225A (en) | Aav cardiac gene therapy for cardiomyopathy | |
IL289826A (en) | Modified aav capsid proteins for treatment of arthritic disease | |
IL284113A (en) | Compounds for the reduction of the deleterious activity of extended nucleotide repeat containing genes | |
ZA201907460B (en) | Improved protocol for treatment of lupus nephritis | |
IL289201A (en) | Compounds for treatment of cancer | |
EP4034168A4 (en) | Methods for depletion of deleterious mitochondrial genomes | |
GB201911056D0 (en) | Treatment of ADD/ADHD | |
GB201907305D0 (en) | Treatment of conditions | |
EP3976069A4 (en) | Fibroblast therapy for treatment of duchenne muscular dystrophy | |
IL284749A (en) | Treatment of pitt-hopkins syndrome | |
IL284747A (en) | Minocycline for the treatment of pitt-hopkins syndrome | |
ZA202201080B (en) | Improved medical apparatus for containing haematomas | |
IL291012A (en) | Method for the compression of genome sequence data | |
GB201917253D0 (en) | Treatment of conditions | |
GB201915768D0 (en) | Treatment of lung conditions | |
GB201809356D0 (en) | PetaQuantum genome analyzer |